SEC Tracker
Get the app

Repligen RGEN

Repligen FY 2024: net loss $25.5M; diluted EPS −$0.46

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Repligen reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$25.5M−172% from $35.6M in FY 202310-K income statement, on EDGAR
  2. Diluted EPS−$0.46−173% from $0.63 in FY 202310-K income statement, on EDGAR
  3. Cash and cash equivalents$757.4M+1% from $751.3M in FY 2023Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
  4. Cash from operations$175.4M+54% from $113.9M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Repligen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Corcept Therapeutics CORT public float $6.1B, Jun 30, 2025
  2. Jazz Pharmaceuticals JAZZ public float $6.3B, Jun 30, 2025
  3. Madrigal Pharmaceuticals MDGL public float $5.6B, Jun 30, 2025
  4. Revolution Medicines RVMD public float $6.7B, Jun 30, 2025
  5. Biomarin Pharmaceutical BMRN public float $6.7B, Jun 30, 2025